肽受体放射性核素治疗后剂量限制性骨髓毒性在女性中比男性更常见
本研究基于2000至2015年II期试验中接受177Lu-DOTATATE治疗的神经内分泌肿瘤患者,比较男女发生剂量限制性骨髓、肝、肾毒性的差异。女性(n=439)与男性(n=534)中位给药活度均为29.6 GBq(800 mCi),女性≥2级血小板减少(25% vs 18%,P=0.004)、≥3级血小板减少(11% vs 6%,P=0.008)及≥3级贫血(7% vs 3%,P=0.002)发生率均高于男性。多变量回归显示女性是≥2级血小板减少的独立危险因素(OR 2.50,95%CI 1.67-3.74)。
要点
- 女性神经内分泌肿瘤患者PRRT后≥2级血小板减少发生率25% vs 男性18%(P=0.004)。
- 女性≥3级血小板减少11% vs 男性6%(P=0.008),≥3级贫血7% vs 男性3%(P=0.002)。
- 女性是≥2级血小板减少的独立危险因素(OR 2.50,95%CI 1.67-3.74)。
核心结论
- 女性神经内分泌肿瘤患者比男性更常发生PRRT诱导的血小板和血红蛋白毒性,但未导致累积活度降低。
研究设计与样本
- 纳入2000至2015年在本中心II期试验中接受177Lu-DOTATATE治疗且有可用实验室数据的神经内分泌肿瘤患者。
- 对从PRRT开始至末次周期后3个月内发生的所有剂量限制性毒性,按常见不良事件术语标准(版本4.03)记录最高分级。
主要发现
- 基线时女性(n=439)的体重指数、卡氏功能状态评分、血红蛋白水平和肌酐清除率显著低于男性(n=534),血小板水平显著高于男性。
- 两组中位给药活度均为29.6 GBq(800 mCi)。
- 女性≥2级血小板减少发生率为25% vs 男性18%(P=0.004),源于≥3级血小板减少显著增加(11% vs 6%,P=0.008)。
- 女性≥3级贫血发生率高于男性(7% vs 3%,P=0.002)。
- 多变量回归模型中,女性(OR 2.50,95%CI 1.67-3.74)被确认为≥2级血小板减少的独立危险因素,模型中还纳入基线血小板计数、骨转移、111In-DTPA-奥曲肽扫描摄取、卡氏功能状态评分、碱性磷酸酶、淋巴细胞、白蛋白和肾功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Peptide receptor radionuclide therapy (PRRT) can cause dose-limiting toxicities (DLTs) of the bone marrow, liver, and kidneys. It is yet unknown whether women and men are equally at risk of these DLTs. METHODS: Neuroendocrine tumor patients treated with 177Lu-DOTATATE between 2000 and 2015 in our phase II trial with available laboratory data were included. For all DLTs, the highest Common Terminology Criteria for Adverse Events (version 4.03) grades that occurred from the start of PRRT until 3 months after the last cycle were scored. RESULTS: At baseline, women (n = 439) had a significantly lower body mass index, Karnofsky Performance Score, hemoglobin level, and creatinine clearance and a significantly higher platelet level than men (n = 534). Both groups received a median activity of 29.6 GBq (800 mCi). After the start of PRRT, women more frequently developed grade ≥2 thrombocytopenia compared with men (25% vs 18%, P = 0.004) due to a significant increase in grade ≥3 thrombocytopenia (11% vs 6%, P = 0.008). Furthermore, the incidence of grade ≥3 anemia was higher in women (7% vs 3%, P = 0.002). In the multivariable regression model, female sex (odds ratio, 2.50; 95% confidence interval, 1.67-3.74) was confirmed to be an independent risk factor for grade ≥2 thrombocytopenia, among baseline platelet count, bone metastases, uptake on 111In-DTPA-octreotide scan, Karnofsky Performance Score, alkaline phosphatase, lymphocytes, albumin, and renal function. CONCLUSIONS: Female neuroendocrine tumor patients more often experienced PRRT-induced toxicities of platelets and hemoglobin than males, but this did not lead to a lower cumulative activity.
引用
- Minczeles NS, de Herder WW, Konijnenberg MW, et al. Dose-Limiting Bone Marrow Toxicities After Peptide Receptor Radionuclide Therapy Are More Prevalent in Women Than in Men. Clin Nucl Med. 2022. PMID: 35426841. doi:10.1097/RLU.0000000000004203
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。